FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W168224373> ?p ?o ?g. }

• W168224373 abstract "The aim of this research thesis was to explore the structure-activity relationship (SAR) of ferrocenyl-peptide bioconjugates and to explore methods by which these compounds exert their anti-proliferative on cancer cells. Furthermore, the applicability across different cell types including cancer cells which have acquired resistance to chemotherapeutics and non-cancerous cells was investigated. Finally, we attempted to overcome the insolubility of the ferrocene compounds in a liquid which is suitable for delivery in vivo.We evaluated a panel of novel ferrocenyl-peptide bioconjugates for their anti-cancer potential in lung and melanoma cells. Utilizing structure-activity relationship (SAR) studies we found the anti-proliferative activity of the compounds tested varies greatly depending on the configuration of the compound. Two of the most active compounds N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl and methyl ester showed IC50 values in the nanomolar range. Cisplatin was used as a comparison and was found to have higher IC50 values.From these SAR studies the following trends were observed:1.1-alkyl-1’- N-ortho- derivatives exhibited lower growth inhibition compared to the meta and para derivatives for the dipeptides employed 2.Cytotoxicity of the 1-alkyl-1’-N-para, N-meta and N-ortho-(ferrocenyl) benzoyl dipeptide esters, decreases with the increase of the size of the alkyl group incorporated (propyl < ethyl < methyl) on the ferrocene moiety3.The order of the amino acids in the dipeptide chain is crucial for activity, the trend being Gly Gly > Gly L-Ala > Gly L-Leu > Gly L-Phe.4.The presence of the ethynyl moiety does not result in any significant enhancement of the anti-proliferative effect of the N-(ferrocenyl) benzoyl and naphthoyl dipeptide derivatives. 5.Replacing the ethyl ester in the previously most active, N-(6-ferrocenyl-2-naphthoyl) glycine glycine ethyl ester, with a methyl ester further increases its activity.Two of the biggest factors which affect the use of chemotherapeutic drugs in a clinical setting are the side-effects caused by the drug and also resistance of the cancer cells to the drug. We have addressed this issue by testing the most active compounds from the SAR studies in cell lines which have been made resistant to two common chemotherapeutics, cisplatin and temozolomide. We also tested the two most active compounds in normal human dermal fibroblast (NHDF) cells as an indicator of the effect which the compounds would have on healthy tissue. Results were favourable as one of the compounds was able to overcome the resistance and both compounds showed less cytotoxicity against NHDF than cisplatin.We analysed the effect the most active compound had on the cell cycle in lung cancer and melanoma cells. We observed an increase in the sub-G0 fraction which is indicative of apoptosis. Induction of apoptosis was confirmed using the TUNEL assay which detects late stage apoptotic cells.Due to the insolubility it was not possible to test the compounds in vivo. However, we tested a range of approaches to improve their solubility for future in vivo testing.From the results gathered, a number of conclusions can be made. It is clear that chemical structure of the ferrocenyl compounds plays an important role in their activity levels. A key aspect in the mode of action of the compound tested is the induction of apoptosis/necorsis. With resistance to chemotherapeutics being an ongoing problem in cancer treatment, the ability of a compound to overcome resitance to important chemotherapeutics while having a significantly lower activity level in normal human cells is an appealing characterstic of the tested compound. Finally, the issue with solubility has, at the time of writing this research thesis, been unsolved. However, with promising research being undertaken in the field of improving solubility of compounds, the future looks hopeful." @default.
• W168224373 created "2016-06-24" @default.
• W168224373 creator A5072424846 @default.
• W168224373 date "2014-03-01" @default.
• W168224373 modified "2023-09-24" @default.
• W168224373 title "Biological evaluation of N-Ferrocenyl amino acid and dipeptide ester derivatives as potential anti-cancer agents and investigation into their mode of action in preparation for in vivo evaluation." @default.
• W168224373 hasPublicationYear "2014" @default.
• W168224373 type Work @default.
• W168224373 sameAs 168224373 @default.
• W168224373 citedByCount "0" @default.
• W168224373 crossrefType "dissertation" @default.
• W168224373 hasAuthorship W168224373A5072424846 @default.
• W168224373 hasConcept C109316439 @default.
• W168224373 hasConcept C147789679 @default.
• W168224373 hasConcept C150903083 @default.
• W168224373 hasConcept C17525397 @default.
• W168224373 hasConcept C178790620 @default.
• W168224373 hasConcept C185592680 @default.
• W168224373 hasConcept C202751555 @default.
• W168224373 hasConcept C207001950 @default.
• W168224373 hasConcept C21951064 @default.
• W168224373 hasConcept C2776568683 @default.
• W168224373 hasConcept C2777237805 @default.
• W168224373 hasConcept C2777752497 @default.
• W168224373 hasConcept C2777756961 @default.
• W168224373 hasConcept C2779138802 @default.
• W168224373 hasConcept C2779281246 @default.
• W168224373 hasConcept C2780263894 @default.
• W168224373 hasConcept C515207424 @default.
• W168224373 hasConcept C52859227 @default.
• W168224373 hasConcept C55493867 @default.
• W168224373 hasConcept C71240020 @default.
• W168224373 hasConcept C86803240 @default.
• W168224373 hasConceptScore W168224373C109316439 @default.
• W168224373 hasConceptScore W168224373C147789679 @default.
• W168224373 hasConceptScore W168224373C150903083 @default.
• W168224373 hasConceptScore W168224373C17525397 @default.
• W168224373 hasConceptScore W168224373C178790620 @default.
• W168224373 hasConceptScore W168224373C185592680 @default.
• W168224373 hasConceptScore W168224373C202751555 @default.
• W168224373 hasConceptScore W168224373C207001950 @default.
• W168224373 hasConceptScore W168224373C21951064 @default.
• W168224373 hasConceptScore W168224373C2776568683 @default.
• W168224373 hasConceptScore W168224373C2777237805 @default.
• W168224373 hasConceptScore W168224373C2777752497 @default.
• W168224373 hasConceptScore W168224373C2777756961 @default.
• W168224373 hasConceptScore W168224373C2779138802 @default.
• W168224373 hasConceptScore W168224373C2779281246 @default.
• W168224373 hasConceptScore W168224373C2780263894 @default.
• W168224373 hasConceptScore W168224373C515207424 @default.
• W168224373 hasConceptScore W168224373C52859227 @default.
• W168224373 hasConceptScore W168224373C55493867 @default.
• W168224373 hasConceptScore W168224373C71240020 @default.
• W168224373 hasConceptScore W168224373C86803240 @default.
• W168224373 hasLocation W1682243731 @default.
• W168224373 hasOpenAccess W168224373 @default.
• W168224373 hasPrimaryLocation W1682243731 @default.
• W168224373 hasRelatedWork W1963554836 @default.
• W168224373 hasRelatedWork W2013557121 @default.
• W168224373 hasRelatedWork W2029592871 @default.
• W168224373 hasRelatedWork W2061785914 @default.
• W168224373 hasRelatedWork W2566485165 @default.
• W168224373 hasRelatedWork W2624676977 @default.
• W168224373 hasRelatedWork W2793428471 @default.
• W168224373 hasRelatedWork W2900965797 @default.
• W168224373 hasRelatedWork W2926650861 @default.
• W168224373 hasRelatedWork W2947633421 @default.
• W168224373 hasRelatedWork W2950002298 @default.
• W168224373 hasRelatedWork W2966691090 @default.
• W168224373 hasRelatedWork W3008179741 @default.
• W168224373 hasRelatedWork W3107659846 @default.
• W168224373 hasRelatedWork W3115527398 @default.
• W168224373 hasRelatedWork W3202609930 @default.
• W168224373 hasRelatedWork W3210347017 @default.
• W168224373 hasRelatedWork W89249882 @default.
• W168224373 hasRelatedWork W1949422131 @default.
• W168224373 hasRelatedWork W2901773134 @default.
• W168224373 isParatext "false" @default.
• W168224373 isRetracted "false" @default.
• W168224373 magId "168224373" @default.
• W168224373 workType "dissertation" @default.